Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Jan 24;2007(1):CD001216.
doi: 10.1002/14651858.CD001216.pub2.

Screening for colorectal cancer using the faecal occult blood test, Hemoccult

P Hewitson  1 , P Glasziou, L Irwig, B Towler, E Watson
Affiliations
Meta-Analysis

Screening for colorectal cancer using the faecal occult blood test, Hemoccult

P Hewitson et al. Cochrane Database Syst Rev. .

Abstract

Background: Colorectal cancer is a leading cause of morbidity and mortality, especially in the Western world. The human and financial costs of this disease have prompted considerable research efforts to evaluate the ability of screening tests to detect the cancer at an early curable stage. Tests that have been considered for population screening include variants of the faecal occult blood test, flexible sigmoidoscopy and colonoscopy. Reducing mortality from colorectal cancer (CRC) may be achieved by the introduction of population-based screening programmes.

Objectives: To determine whether screening for colorectal cancer using the faecal occult blood test (guaiac or immunochemical) reduces colorectal cancer mortality and to consider the benefits, harms and potential consequences of screening.

Search strategy: Published and unpublished data for this review were identified by: Reviewing studies included in the previous Cochrane review; Searching several electronic databases (Cochrane Library, Medline, Embase, CINAHL, PsychInfo, Amed, SIGLE, HMIC); and Writing to the principal investigators of potentially eligible trials.

Selection criteria: We included in this review all randomised trials of screening for colorectal cancer that compared faecal occult blood test (guaiac or immunochemical) on more than one occasion with no screening and reported colorectal cancer mortality.

Data collection and analysis: Data from the eligible trials were independently extracted by two reviewers. The primary data analysis was performed using the group participants were originally randomised to ('intention to screen'), whether or not they attended screening; a secondary analysis adjusted for non-attendence. We calculated the relative risks and risk differences for each trial, and then overall, using fixed and random effects models (including testing for heterogeneity of effects). We identified nine articles concerning four randomised controlled trials and two controlled trials involving over 320,000 participants with follow-up ranging from 8 to 18 years.

Main results: Combined results from the 4 eligible randomised controlled trials shows that participants allocated to screening had a 16% reduction in the relative risk of colorectal cancer mortality (RR 0.84, CI: 0.78-0.90). In the 3 studies that used biennial screening (Funen, Minnesota, Nottingham) there was a 15% relative risk reduction (RR 0.85, CI: 0.78-0.92) in colorectal cancer mortality. When adjusted for screening attendance in the individual studies, there was a 25% relative risk reduction (RR 0.75, CI: 0.66 - 0.84) for those attending at least one round of screening using the faecal occult blood test.

Authors' conclusions: Benefits of screening include a modest reduction in colorectal cancer mortality, a possible reduction in cancer incidence through the detection and removal of colorectal adenomas, and potentially, the less invasive surgery that earlier treatment of colorectal cancers may involve. Harmful effects of screening include the psycho-social consequences of receiving a false-positive result, the potentially significant complications of colonoscopy or a false-negative result, the possibility of overdiagnosis (leading to unnecessary investigations or treatment) and the complications associated with treatment.

PubMed Disclaimer

Conflict of interest statement

There are no other potential conflicts of interest relating to this review.

Update of

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Funen 1996 {published data only}
    1. Kronborg, O, Fenger, C, Olsen, J, Jorgensen, O.D, Sondergaard, O. Randomised study of screening for colorectal cancer with faecal‐occult‐blood test. Lancet 1996;348(9040):1467‐1471. - PubMed
Funen 2002 {published data only}
    1. Jorgensen, O.D, Kronborg, O, Fenger, C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002;50:29‐32. - PMC - PubMed
Funen 2004 {published data only}
    1. Kronborg, O, Jorgensen, O.D, Fenger, C, Rasmussen, M. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand.J.Gastroenterol 2004;39(9):846‐851. - PubMed
Goteborg 1994 {published data only}
    1. Kewenter, J, Brevinge, H, Engaras, B, Haglind, E, Ahren, C. Results of screening, rescreening, and follow‐up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand.J.Gastroenterol 1994;29(5):468‐473. - PubMed
Goteborg 1996 {published data only}
    1. Kewenter, J, Brevinge, H. Endoscopic and surgical complications of work‐up in screening for colorectal cancer. Dis. Colon. Rectum 1996;39:676‐680. - PubMed
Goteborg 2005 {unpublished data only}
    1. Haglind, E, Lindholm, E. Personel Communication Sept 2005.
Goteborg 2008 {published data only}
    1. Lindholm, E, Brevinge, H, Haglind, E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.. British Journal of Surgery 2008;95(8):1029‐1036. - PubMed
Minnesota 1993 {published data only}
    1. Mandel, J.S, Bond, J.H, Church, T.R, Snover, D.C, Bradley, G.M, Schuman, L.M, Ederer, F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N.Engl.J.Med 1993;328(19):1365‐1371. - PubMed
Minnesota 1999 {published data only}
    1. Mandel, J.S, Church, T.R, Ederer, F, Bond, J.H. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J.Natl.Cancer.Inst 1999;91(5):434‐437. - PubMed
Minnesota 2000 {published data only}
    1. Mandel, J.S, Church, T.R, Bond, J.H, Ederer, F, Geisser, M.S, Mongin, S.J, Snover, D.C, Schuman, L.M. The effect of fecal occult‐blood screening on the incidence of colorectal cancer. N.Engl.J.Med 2000;343(22):1603‐1607. - PubMed
Nottingham 1996 {published data only}
    1. Hardcastle, J.D, Chamberlain, J.O, Robinson, M.H, Moss, S.M, Amar, S.S, Balfour, T.W, James, P.D, Mangham, C.M. Randomised controlled trial of faecal‐occult‐blood screening for colorectal cancer. Lancet 1996;348(9040):1472‐1477. - PubMed
Nottingham 1999 {published data only}
    1. Robinson, M.H, Hardcastle, J.D, Moss, S.M, Amar, S.S, Chamberlain, J.O, Armitage, N.C, Scholefield, J.H, Mangham, C.M. The risks of screening: data from the Nottingham randomised controlled trial of faecal occult blood screening for colorectal cancer. Gut 1999;45(4):588‐592. - PMC - PubMed
Nottingham 2002 {published data only}
    1. Scholefield, J.H, Moss, S, Sufi, F, Mangham, C.M, Hardcastle, J.D. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut 2002;50(6):840‐844. - PMC - PubMed

References to studies excluded from this review

Almpoea 2004 {published data only}
    1. Chrissidis, T, Saliangas, K, Economou, A, Nikoloudis, N, Andreadis, E, Prodromou, K, Georgakis, K. Mass screening for colorectal cancer: compliance in the Almopea Region. Tech.Coloproct. 2004;8((S1)):193‐195. - PubMed
Beijing 2004 {published data only}
    1. Shi‐Rong, L, Su‐Li, T, Zi‐Tao, W, Ying, H, Jian‐Qui, S, Ge, G, Chang‐Hong, X, Jian‐Biao, C, Zhi‐Min, C, Zhi‐Hong, W, Ya‐Lin, L. Application of fecal occult blood test in consecutive screening of colorectal carcinoma for natural population. World Chin. J. Digestol. 2004;12(1):137‐139.
Burgundy 2004 {published data only}
    1. Faive, J, Dancourt, V, Lejeune, C, Tazi, M.A, Lamour, J, Gerard, D, Dassonville, F, Bonithon‐Kopp, C. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004;126:1674‐1680. - PubMed
California 1993 {published data only}
    1. Selby, J.V, Friedman, G.D, Quesenberry, C.P.J, Weiss, N.S. Effect of fecal occult blood testing on mortality from colorectal cancer. A case control study. Ann. Intern. Med. 1993;118(1):1‐6. - PubMed
Calvados 1996 {published data only}
    1. Launoy, G, Herbert, C, Vallee, J.P, Desoubeaux, N, Reaud, J.M, Ollivier, V, Bouvier, V, Flachs, A, Arsene, D, Valla, A, Gignoux, M. Mass screening for colorectal cancer in France. Experience in 165,000 people in the department of Calvados [Le depistage de masse du cancer colorectal en France. Experience aupres de 165,000 personnes dans le Calvados]. Gastroenterol. Clin. Biol. 1996;20(3):228‐236. - PubMed
Florence 1997 {published data only}
    1. Zappa, M, Castiglione, G, Grazzini, G, Falini, P, Giorgi, D, Paci, E, Ciatto, S. Effect of faecal occult blood testing on colorectal mortality: results of a population‐based case‐control study in the district of Florence, Italy. Int. J. Cancer 1997;73(2):208‐210. - PubMed
Guildford 2001 {published data only}
    1. Lamah, M, Norris, J, Caffarey, S.M, Broughton, M, Marks, C.G. Effect of faecal occult blood testing on colorectal cancer mortality in the surveillance of subjects at moderate risk of colorectal neoplasia: a case‐control study.. Int. J. Colorectal Dis. 2001;16(5):313‐317. - PubMed
Italy 2010 {published data only}
    1. Lisi, D, Hassan, C.C, Crespi, M, AMOD Study Group. Participation in colorectal cancer screening with FOBT and colonoscopy: An Italian, multicentre, randomized population study. Digestive and Liver Disease 2010;42(5):371‐376. - PubMed
Japan 1995 {published data only}
    1. Saito, H, Soma, Y, Koeda, J, Wada, T, Kawaguchi, H, Sobue, T, Aisawa, T, Yoshida, Y. Reduction in the risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test: a case‐control study. Int. J. Cancer 1995;61(4):465‐469. - PubMed
Jiashan 2003 {published data only}
    1. Zheng, S, Chen, K, Liu, X, Ma, X, Yu, H, Chen, K, Yao, K, Zhou, L, Wang, L, Qui, P, Deng, Y, Zhang, S. Cluster randomization trial of sequence mass screening for colorectal cancer. Dis. Colon. Rectum. 2003;46(1):51‐58. - PubMed
Milan 1999 {published data only}
    1. Bertario, L, Russo, A, Crosignani, P, Sala, P, Spinelli, P, Pizzetti, P, Andeola, S, Berrino, F. Reducing colorectal cancer mortality by repeated faecal occult blood test: a nested case‐control study. Eur. J. Cancer 1999;35(6):973‐977. - PubMed
Netherlands 2008 {published data only}
    1. van Rossum, L.G, van Rijn, A.F, Laheij, R.J, van Oijen, M.G, Fockens, P, van Krieken, H.H, Verbeek, A.L, Jansen, J.B, Dekker, E. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135(1):82‐90. - PubMed
Netherlands 2009 {published data only}
    1. Hol, L, Wilschut, J.A, van, Ballegooijen M, van Vuuren, A.J, van, der, V, Reijerink, J.C, Togt, A.C, Kuipers, E.J, Habbema, J.D, van Leerdam, M.E. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut‐off levels. British Journal of Cancer 2009;100(7):1103‐1110. - PMC - PubMed
Netherlands 2010 {published data only}
    1. Hol, L, van Leerdam, M.E, van, Ballegooijen M, van Vuuren, A.J, van, Dekken H, Reijerink, J.C, Togt, A.C, Habbema, J.D, Kuipers, E.J. Screening for colorectal cancer: randomised trial comparing guaiac‐based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59(1):62‐68. - PubMed
New York 1993 {published data only}
    1. Winawer, S.J, Flehinger, B.J, Schottenfeld, D, Miller, D.G. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J. Nat. Cancer. Instit. 1993;85:1311‐1318. - PubMed
Saarland 1993 {published data only}
    1. Wahrendorf, J, Robra, B.P, Weibelt, H, Oberhausen, R, Weiland, M, Dhom, G. Effectiveness of colorectal cancer screening: results from a population‐based case‐control evaluation in Saarland. Eur. J. Cancer Prev. 1993;2(3):221‐227. - PubMed
Turin 2010 {published data only}
    1. Senore, C, Armaroli, P, Silvani, M, Andreoni, B, Bisanti, L, Marai, L, Castiglione, G, Grazzini, G, Taddei, S, Gasperoni, S, Giuliani, O, Malfitana, G, Marutti, A, Genta, G, Segnan, N. Comparing different strategies for colorectal cancer screening in Italy: predictors of patients' participation. American Journal of Gastroenterology 2010;105(1):188‐198. - PubMed
Tuscany 2008 {published data only}
    1. Costantini, A.S, Martini, A, Puliti, D, Ciatto, S, Castiglione, G, Grazzini, G, Zappa, M. Colorectal cancer mortality in two areas of Tuscany with different screening exposures. Journal of the National Cancer Institute 2008;100(24):1818‐1821. - PubMed
Washington 1995 {published data only}
    1. Lazovich, D, Weiss, N.S, Stevens, N.G, White, E, McKnight, B, Wagner, E.H. A case‐control study to evaluate the efficacy of screening for faecal occult blood. J. Med. Screen. 1995;2(2):84‐89. - PubMed

Additional references

AIHW 2001
    1. Australasian Association of Cancer Registries. Cancer in Australia 2001. Australian Institute of Health and Welfare, 2004.
Alderson 2005
    1. Alderson P, Green S, Higgins JPT, Editors. The Cochrane Handbook of Systematic Reviews and Interventions 4.2.5 [Updated May 2005]. The Cochrane Library. Chichester: John Wiley & Sons Ltd., 2005, issue 2.
Atkin 2010
    1. Atkin, W.S, Edwards, R, Kralj‐Hans, I, Wooldrage, K, Hart, A.R, Northover, J.M.A, Parkin, D.M, Wardle, J, Duffy, S.W, Cuzick, J, UK Flexible Sigmoidoscopy Trial Investigators. Once‐only flexible sigmoidoscopy screening in prevention of colorectal cacner: a multicentre randmoised controlled trial.. Lancet 2010;375:1624‐1633.. - PubMed
Black 2002
    1. Black, C, Haggstrom, D.A, Welch, H.G. All‐cause mortality in randomised trials of cancer screening. J. Nat. Cancer. Instit. 2002;94(3):167‐173. - PubMed
Bliss 2004
    1. Bliss, C.M.J, Schroy, P.C. Endoscopic diagnosis and management of hereditary nonpolyposis colorectal cancer. Current Opinion in Gastroenterology 2004;20:468‐473. - PubMed
Cappell 2005
    1. Cappell, M.S. The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Medical Clinics of North America 2005;89:1‐42. - PubMed
Church 1997
    1. Church, T.R, Ederer, F, Mandel, J.S. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test. Journal of the National Cancer Institute 1997;89:1440‐1448. - PubMed
Citarda 2001
    1. Citarda, F, Tomaselli, G, Capocaccia, R, Barcherini, S, The Italian Multicentre Study Group. Efficacy is standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001;48:812‐815. - PMC - PubMed
Cochrane Handbook 5.0.2
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009.
Ederer 1997
    1. Ederer, F, Church, T.R, Mandel, J.S. Fecal occult blood screening in the Minnesota study: role of chance detection of lesions. Journal of the National Cancer Institute 1997;89:1423‐1428. - PubMed
Faivre 2002
    1. Faivre, J, Bouvier, A, Bonithon‐Kopp, C. Epidemiology and screening of colorectal cancer. Best Practice Res. Clin. Gastronent. 2002;16(2):187‐199. - PubMed
Federici 2005
    1. Federici, A, Rossi, P.G, Borgia, P, Bartolozzi, F, Farchi, S, Gausticchi, G. The immunochemical faecal occult blood test leads to higher compliance than guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.. J Med Screen 2005;12:83‐88. - PubMed
Glasziou 1992
    1. Glasziou, P.P. Meta‐analysis adjusting for compliance: the example of screening for breast cancer.. J. Clin. Epidemiol. 1992;79:488‐494. - PubMed
Glasziou 1995
    1. Glasziou, P.P, Irwig, L.M. An evidence based approach to individualising treatment.. BMJ 1995;311:1356‐1359. - PMC - PubMed
Guittet 2009
    1. Guittet, L, Bouvier, V, Mariotte, N, Vallee, J.P, Levillain, R, Tichet, J, Launoy, G. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location.. British Journal of Cancer 2009;100:1230‐1235. - PMC - PubMed
Hoff 2009
    1. Hoff, G, Grotmol, T, Skovlund, E, Bretthauer, M, for the Norwegian Colorectal Cancer Prevention Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial.. BMJ 2009;338:b1846. - PMC - PubMed
Kronborg 1989
    1. Kronborg, O, Fenger, C, Olsen, J, Bech, K, Sondergaard, O. Repeated screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Funen, Denmark. Scand. J. Gastroenterol. 1989;24:599‐606. - PubMed
Lang 1994
    1. Lang, C.A, Ransohoff D.F. Fecal occult blood screening for colorectal cancer. Is mortality reduced by chance selection for screening colonoscopy?. JAMA 1994;271:1011‐1013. - PubMed
Liu 2000
    1. Liu, X, Zheng, S, Chen, K, Ma, X, Zhou, L, Yu, H, Yao, K, Chen, K, Cai, S, Zhang, S. Randomized controlled trial of sequence mass screening program for colorectal cancer. Zhonghua.Liu.Xing.Bing.Xue.Za.Zhi. 2000;21(6):430‐433. - PubMed
Lynch 2000
    1. Lynch, H.T, Lynch, J.F. Hereditary nonpolyposis colorectal cancer. Seminars in Surgical Oncology 2000;18:305‐313. - PubMed
ONS 2004
    1. Office of National Statistics. Mortality statistics cause: review of the registrar general on deaths by cause, sex and age in England and Wales, 2004. Office for National Statistics, 2005.
ONS 2005
    1. Office of National Statistics. Cancer Statistics Registrations: Registrations of cancer diagnosed in 2002. Office for National Statistics, 2005.
Segnan 2005
    1. Segnan, N, Senore, C, Andreoni, B, Arrigoni, A, Bisanti, L, Cardelli, A, Castiglione, G, Crosta, C, DiPlacido, R, Ferrari, A, Ferraris, R, Ferrero, F, Francchia, M, Gasperoni, S, Malfitana, G, Recchia, S, Rizzetto, M, Saracco, G, Spandre, M, Turco, D, Turco, P, Zappa, M, and the SCORE2 Working Group‐Italy. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.. JNCI 2005;97:347‐357. - PubMed
Towler 1998
    1. Towler, B, Irwig, L, Glasziou, P, Kewenter, J, Weller, D, Silagy, C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult. BMJ 1998;317:559‐565. - PMC - PubMed
U.S. CDC 2004
    1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2001 Incidence and Mortality. Department of Health and Social Services, Centres for Disease Control and Prevention and National Cancer Institute., 2004.
Weissfeld 2005
    1. Weissfeld, J.L, Schoen, R.E, Pinsky, P.F, Bresalier, R.S, Church, T, Yurgalevitch, S, Austin, J.H, Prorok, P.C, Gohagan, J.K, for the PLCO Project Team. Flexible sigmoidoscopy in the PLCO Cancer Screening Trial: results from baseline screening examination of a randomized trial.. JNCI 2005;97:989‐997. - PubMed
Weitz 2005
    1. Weitz, J, Koch, M, Debus, J, Hohler, T, Galle, P.R, Buchler, M.W. Colorectal cancer. Lancet 2005;365:153‐165. - PubMed
Winawer 1993
    1. Winawer, S.J, Zauber, A.G, Ho, M.A, O'Brien, M.J, Gottlieb, L.S, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Eng J Med 1993;329:1977‐1981. - PubMed